News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fresenius SE Hit By U.S. Cuts, Weak Blood Substitute Sales


5/6/2014 7:01:01 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

First quarter earnings at German healthcare group Fresenius SE grew more slowly than expected, hurt by spending cuts in the United States and China and lower sales of a blood substitute product. The drugmaker, which also operates hospitals and controls dialysis provider Fresenius Medical Care, said on Tuesday adjusted net income rose 2 percent to 228 million euros ($316 million), short of the 244 million euro average estimate in a Reuters poll. Its generic injectable drugs business suffered from price cuts in China and lower sales of a blood substitute called HES, an emergency treatment for sudden blood loss.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters

comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES